Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair of Bladder Cancer Research, shared a post on LinkedIn:
“Look for these exciting trials in progress posters explaining rationale and design of promising strategies:
1) potent all-oral neoadjuvant androgen blockade (Relugolix + Darolutamide) preceding radical prostatectomy for high-risk localized/locally advanced prostate cancer- objectives of safety, activity and potentially enabling tailored adjuvant therapy informed by post-op PSA nadir in the presence of normal testosterone levels-investigator-initiated trial supported by Bayer, Sumitomo Pharma Oncology and colleagues Vipul Patel, Marcio Covas Moschovas, Ritika Behera, and many others,
2) perioperative pembrolizumab + V940 (mRNA coding up to 34 neoantigens customized for each patient) +/- EV for muscle-invasive bladder cancer – Merck, Moderna, Shilpa Gupta, Tom Powles, Abhishek Bavle, – honored to present from Advent Health Central Florida Cancer Institute.”
